Paul Blanchfield, President, Lantheus : Rana, thanks for the question. So the MIRROR study is our study to assess the use of PSMA PET with Polarify in the intermediate favorable setting. As a reminder, this is not necessarily, if you will, a registrational study, because Polarify has a very broad label in the staging where it identifies the risk of metastases, but it doesn't distinguish the level of risk. And so the NCCN and the FMMI and other guidelines agencies has effectively recommended use of PSMA PET with Polarify in their intermediate unfavorable and the high and very high risk patient population. We began studying PSMA PET with Clarify in intermediate favorable patients last year.